Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:CEO |
gptkb:Troyen_A._Brennan
|
| gptkbp:clinicalTrials |
ongoing studies
|
| gptkbp:employees |
approximately 1,000
|
| gptkbp:focus |
treatment of gastrointestinal diseases
|
| gptkbp:founded |
2001
|
| gptkbp:headquarters |
gptkb:Bridgewater,_New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Salix Pharmaceuticals
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:parentCompany |
gptkb:Bausch_Health_Companies
|
| gptkbp:partnerships |
various research institutions
|
| gptkbp:products |
gptkb:Apriso
Relistor Xifaxan Uceris Zelnorm |
| gptkbp:revenue |
$1.2 billion (2020)
|
| gptkbp:specializesIn |
gastroenterology
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.salix.com
|